|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Earnings: Tough Times Ahead
Author(s)Kevin Gopal
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
Advertisement
Articles in this issue
about 25 years ago
Research: New Horizonsabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Privacy, Pediatrics, and Policyabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Shortage: Vaccine Worriesabout 25 years ago
Gateway to Japanabout 25 years ago
SurroundedAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5